期刊文献+

MDM2和p53在宫颈鳞癌中的表达及与高危型HPV感染的关系 被引量:6

Relationship between Expression of MDM2,p53 and HR-HPV in Patients with Cervical Squamous Cancer
下载PDF
导出
摘要 目的探讨宫颈鳞癌组织中MDM2、p53的表达及与高危型人乳头瘤病毒(HPV)感染的关系。方法选取实验组30例宫颈鳞癌组织及对照组20例正常宫颈组织,石蜡包埋后,采用免疫组化法检测组织中MDM2、p53蛋白的表达;采用杂交捕获二代实验(HC2)的方法检测实验组及对照组宫颈分泌物中高危型HPV的表达。结果 MDM2、p53在宫颈鳞癌组织中的表达阳性率分别为90%、86.7%,高危型HPV(HR-HPV)在宫颈鳞癌患者宫颈分泌物中的检出率为83.3%;p53在HR-HPV阳性的宫颈鳞癌患者中阳性表达率为92%,与对照组比较差异均有统计学意义(P<0.05);经Spearman相关分析显示,P53与高危型HPV在宫颈鳞癌中的表达呈正相关(r=0.822,P<0.05)。结论 MDM2、p53与宫颈鳞癌的发生有关;高危型HPV感染可能是p53由抑癌基因转变为癌基因的关键因素。 Objective To detect the expression of MDM2, p53 and HR - HPV in patients with cervical canc-er. Methods ( 1 ) The expressions of MDM2, p53 were observed by immunihistochemisty in the cervical cancer tissues of 30 cases with cervical squamous cancer and the normal cervial tissues of 20 cases as controls. (2)The expressions of HR - HPV were observed by HC2 in the cervical squamous cancer tissues and normal cervica 1 tissues. Results The positive expression of MDM2,p53 lied in nucleus and the positive rate were 90%and 86.7%. The positive rate of HR - HPV in cervical squamous cancer was 83.3%. There was significantly statistical difference in MDM2 and P53 between and cervical squamous cancer tissues and normal cervical tis-sues. Conclusion The expression of MDM2 and p53 may be a key role in occurrence of cervical squamous cancer.
出处 《宁夏医科大学学报》 2013年第1期26-28,F0004,共4页 Journal of Ningxia Medical University
基金 宁夏自然科学基金(NZ10151)
关键词 宫颈鳞癌 MDM2 P53 高危型人乳头瘤病毒 cervical squamous cancer MDM2 p53 high risk human papillomavirus
  • 相关文献

参考文献9

二级参考文献46

共引文献47

同被引文献62

  • 1Park TC, Kim C J, Koh YM, et al. Human papillmomavirus genoty- ping by the DNA chip in the cervical neoplasia [ J ]. DNA Cell Bio1,2004 ,23 (2) :119-125. 被引量:1
  • 2Zhao FH, Lin M J, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical canc- er:a pooled analysis of individual patient data from 17 population-based studies from China [ J ]. Lancet Oncal, 2011,11 ( 12 ) : 1160-1171. 被引量:1
  • 3谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2012.51-58. 被引量:53
  • 4Weismann D, Briese J, Niemann J, et al. Osteopontin stimu- lates invasion of NCI - h295 cells but is not associated with survival in adrenocortical carcinoma [ J ) . J Pathol, 2009, 218 (2): 232-240. 被引量:1
  • 5Shevde LA, Das S, Clark DW, et al. Osteopontin: an effec- tor and an effect of tumor metastasis [ J ]. Curr Mol Med, 2010, 10 (1): 71-$1. 被引量:1
  • 6Mrochem - Kwarciak J, Mrochen - Domin I, Wojcieszek A, et al. Usefulness of osteopontin (OPN) determinations in ovar- ian cancer patients who underwent first - line chemotherapy [J]. Ginekol Pol, 2011, 82 (12): 911 -917. 被引量:1
  • 7Courter D, Cao H, Kwok S, et al. The RGD domain of hu- man osteopontin promotes tumor growth and metastasis through activation of survival pathways [ J ]. PLoS One, 2010, 5 (3) : e9633. 被引量:1
  • 8Cho H, Hong SW, Oh YJ, et al. Clinical significance of os- teopontin expression in cervical cancer [ J]. J Cancer Res Clin Oncol, 2008, 134 (8) : 909 -917. 被引量:1
  • 9Kazemi M, Salehi Z, Chakosari RJ. TP53 codon 72 polymor- phism and breast cancer in northern Iran[J]. Oncol Res, 2009, 18 (1): 25-30. 被引量:1
  • 10Hoppenot C,Stampler K, Dunton C.Cervical cancer screening in high- and low- resource countries:implications and new developments[J].Obstet Gynecol Surv,2012;67( 10):658-667. 被引量:1

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部